MIP Test for Lupus (SLE) Monitoring
Systemic Lupus Erythematosus
NAActive
Key Facts
About DxTerity
DxTerity is a private, commercial-stage diagnostics company leveraging RNA expression profiling to advance precision medicine in autoimmune diseases. Its core technology, the Modular Immune Profile (MIP), analyzes immune-related gene expression from a simple at-home blood sample to monitor disease activity and treatment response. The company has validated its platform through multiple clinical studies (LIFT, EMPOWER, ELEVATE) and collaborates with research institutions and pharma partners. DxTerity operates on a diagnostics business model, generating early revenue from test kits and research services while aiming to secure broader insurance reimbursement.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus Drugs
| Drug | Company | Phase |
|---|---|---|
| Meta10-19 | Leman Biotech | Phase 1 |
| ELEVATE Clinical Study | DxTerity | Observational Study |
| Native Human Antigen – ANA | Arotec Diagnostics | Commercial |
| Rinvoq (upadacitinib) | AbbVie | Phase 3 |
| NKX019 | Nkarta | Phase 1 |